Company News

    RSS Feed

3D Signatures’ Teloview Software Identifies and Stages Patients with Alzheimer’s Disease from a Cheek Swab


March 21, 2017 | WINNIPEG, MB (March 21, 2017) − 3D Signatures Inc.(TSXV:DXD) (the “Company” or “3DS”), is pleased to announce clinical study results which confirm that based on a swab from the inside of a patient’s cheek, its proprietary TeloViewTM software platform has the ability to identify patients with Alzheimer’s disease (“AD”) and,  … Read More

GeneNews Announces Settlement Agreement with HDL Liquidating Trust

March 10, 2017 | GeneNews (TSX:GEN) subsidiary, GeneNews (USA), Inc.,announced that it has reached a settlement agreement with the HDL Liquidating Trust for an outstanding $US 2,000,000 Secured Demand Promissory Note from the Company’s previously announced acquisitions of the full ownership of Innovative Diagnostic Laboratory.

As quoted in the press release:
On May 19, 2015, GeneNews announced  … Read More

NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016

February 22, 2017 |

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2016.

Fourth Quarter 2016 Highlights:

140% increase in clinical genetic testing volume(1)
122% increase in consolidated revenue to $60.5 million
11% reduction in average cost per clinical genetic  … Read More

Cancer Genetics, Inc. to Receive $1.0 Million in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

February 22, 2017 | Cancer Genetics, Inc. (Nasdaq:CGIX) an emerging leader in enabling precision medicine for oncology through the use of molecular markers and information, announced today that it has received approval for a $1.0 million gross tax credit from the New Jersey Technology Business Tax Certificate Transfer (NOL) Program. After expenses and fees,  … Read More

ToolGen Highlights Study Results Demonstrating Utility of AAV-Compatible Cas9 System in vivo Genome Editing

February 22, 2017 | ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, today announced encouraging data from a study evaluating Campylobacter jejuni Cas9 (CjCas9), the smallest Cas9 orthologue characterized to date, for efficient genome editing in vivo.

Results from the study entitled “In vivo genome editing with a small Cas9 orthologue derived  … Read More

Myriad’s BRACAnalysis CDx® Test Successfully Identified Metastatic Breast Cancer Patients with Improved Outcomes from AstraZeneca’s PARP Inhibitor, Olaparib

February 17, 2017 | Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new findings from the OlympiAD study that show its BRACAnalysis CDx®  test successfully identified patients with HER2-negative metastatic breast cancer who have BRCA mutations and who had improved response with Lynparza (olaparib), AstraZeneca’s PARP inhibitor.

The high  … Read More